Can Melanotan 2 cause melanoma?

Published case reports including Langan et al. 2009 (BMJ) document new melanomas and accelerated progression of dysplastic nevi in MT-II users. These are case reports — they do not establish causation — but they constitute a pharmacovigilance signal serious enough that the UK MHRA, Australian TGA, and EMA issued safety warnings. The mechanism is biologically plausible: MC1R agonism drives melanocyte proliferation.

Is Melanotan 2 approved anywhere?

No. MT-II is not approved by the FDA, EMA, MHRA, TGA, or any other drug regulatory authority. In the US it is sold as a research chemical; in Australia and the UK it is effectively prohibited for human use following safety warnings from regulatory authorities.

What is the priapism risk with Melanotan 2?

MT-II stimulates MC4R in hypothalamic circuits mediating erectile function. Multiple case reports document priapism — prolonged painful erection requiring emergency medical intervention — in MT-II users. This is a documented adverse event, not a theoretical risk.

What is the only approved drug in the melanocortin class?

Afamelanotide (Scenesse, CLINUVEL Pharmaceuticals) is EMA-approved (2014) and FDA-approved (2019) for erythropoietic protoporphyria (EPP) — a rare painful genetic photodermatosis. It is administered as a physician-implanted 16 mg subcutaneous implant. It is not approved for tanning or cosmetic darkening.

Spoke 5.6 · Melanocortin Analog · Safety-Critical · NOT Approved

Melanotan 2: pharmacology, adverse event literature, and why no agency has approved it.

By PeptideRadar Research Desk · April 18, 2026

StructureCyclic heptapeptide analog of α-MSH ReceptorsMC1R, MC3R, MC4R, MC5R (non-selective) Regulatory statusNot approved — any agency Updated2026-04-18

Critical safety warning — read before continuing Melanotan II (MT-II) is not approved for human use by the FDA, EMA, TGA (Australia), MHRA (UK), or any other drug regulatory authority with jurisdiction over drug approvals. Published case reports document new melanomas and rapid progression of dysplastic nevi in individuals who used Melanotan II. Priapism (prolonged painful erection requiring medical intervention) has been reported and attributed to MC4R agonism. The UK MHRA, Australian TGA, and EMA have all issued safety communications about unregistered melanocortin products. This page provides educational and research-context information. It does not constitute medical advice or a protocol for use.

Melanotan II is a synthetic melanocortin analog that produces skin tanning, appetite suppression, and spontaneous erections. It has been circulating in the grey-market research chemical and bodybuilding communities since the 1990s. It has generated melanoma case reports, priapism case reports, and explicit safety warnings from health authorities in the UK, Australia, and the EU. It has never been approved by any drug regulatory authority. This page covers the pharmacology and the adverse event literature without minimising either.

Key points

MT-II is a cyclic heptapeptide analog of alpha-MSH, first synthesized at the University of Arizona (Hadley and Hruby group).
Non-selective melanocortin receptor agonist: MC1R (pigmentation), MC3R (energy homeostasis), MC4R (sexual function), MC5R (exocrine glands).
Case reports: Langan et al. 2009 (BMJ, 338:b277) documented mole changes and melanoma in MT-II users. Multiple additional case series followed, leading to UK MHRA and Australian TGA safety warnings.
Priapism: multiple case reports of prolonged erection requiring emergency intervention, attributed to MC4R agonism.
The only FDA- and EMA-approved compound in this class is afamelanotide (Scenesse) — approved specifically for erythropoietic protoporphyria, not tanning.
MT-II ≠ afamelanotide. Different compound, different receptor selectivity, different safety data, different regulatory history.

Structure and origins

Melanotan II was developed at the University of Arizona by researchers including Mac Hadley and Victor Hruby, working from the 1980s onwards. The compound is a cyclic heptapeptide: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂. Key structural features distinguish it from native alpha-melanocyte-stimulating hormone (α-MSH):

Cyclic backbone. An amide bond between Asp and Lys side chains creates cyclization that confers enzymatic resistance and increases potency compared to linear peptides.
D-Phe substitution. Replacement of natural L-Phe with D-Phe increases receptor affinity and metabolic stability.
Non-selectivity. Native α-MSH is primarily MC1R-selective. MT-II's structural modifications produce pan-melanocortin receptor agonism — activity at MC1R, MC3R, MC4R, and MC5R. This non-selectivity generates multiple off-target effects not present with selective MC1R agonism.

Receptor pharmacology: what each receptor mediates

Receptor	Primary locations	Functions	MT-II effect
MC1R	Melanocytes, immune cells	Melanogenesis; anti-inflammatory signalling	Increased melanin synthesis → skin tanning; mole darkening
MC2R	Adrenal cortex	Cortisol secretion (ACTH receptor)	Minimal MT-II activity at MC2R
MC3R	Brain (hypothalamus), gut, heart	Energy homeostasis, feeding behaviour	Appetite suppression
MC4R	Brain (hypothalamus, brainstem)	Energy balance, sexual function, cardiovascular	Appetite suppression; spontaneous erections; blood pressure changes
MC5R	Exocrine glands, skeletal muscle	Exocrine secretion regulation	Reduced exocrine secretion

The tanning effect is MC1R-mediated. The sexual side effects are MC4R-mediated. The appetite suppression is MC3R/MC4R-mediated. Because MT-II is non-selective, a researcher using it for tanning is simultaneously stimulating MC4R-mediated effects they may not have intended or anticipated.

The adverse event literature: melanoma case reports

Pharmacovigilance signal Case reports cannot establish causation. They can establish that an adverse event occurred in a person who used a compound. The accumulation of multiple case reports with consistent features — new melanoma or accelerated nevi changes in MT-II users — constitutes a pharmacovigilance signal serious enough that health authorities in the UK, Australia, and EU issued warnings. That threshold has been crossed. The information below reflects the published literature as of April 2026.

Langan EA et al. (2009, BMJ, 338:b277). A dermatological case series published in the BMJ reported cases of patients presenting with rapid morphological changes in moles — increased size, altered pigmentation, irregular borders — temporally associated with MT-II use. In several cases, biopsied lesions showed dysplastic or malignant histological features consistent with melanoma or high-grade dysplastic nevi.

Additional melanoma case reports. Multiple published case reports and case series in dermatological and oncological journals have documented similar presentations: individuals using MT-II developing new melanomas or having pre-existing moles undergo rapid changes consistent with malignant transformation. These reports span multiple countries, ages, and skin phototypes.

Biological plausibility. MC1R is expressed by melanocytes and its agonism drives both melanin synthesis and melanocyte proliferation. In individuals with pre-existing dysplastic (pre-malignant) melanocytes, excessive MC1R stimulation could theoretically accelerate the transition from dysplastic to malignant phenotype. This is the same reason that MC1R variants (the "red hair gene") are associated with increased melanoma risk — gain-of-function MC1R signalling correlates with melanoma susceptibility. MT-II's potent sustained MC1R agonism represents a pharmacological version of the same stimulus.

UK MHRA advisory (2009). Following accumulation of case reports, the UK Medicines and Healthcare products Regulatory Agency issued a safety communication noting reports of serious adverse events including melanoma development and recommending against use of unregistered melanocortin tanning products.

Australian TGA warnings. The Australian Therapeutic Goods Administration has issued multiple warnings about unregistered tanning injections, noting reports of serious adverse effects including mole changes, and advising that these products are illegal in Australia for human use.

Priapism: the MC4R adverse event

MT-II's stimulation of MC4R in the hypothalamic-brainstem circuits mediates its pro-erectile effects. This was initially considered a potential therapeutic application — MT-II and the related compound PT-141 (bremelanotide) were investigated for erectile dysfunction and female sexual dysfunction. Bremelanotide received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women — a different compound, administered at defined physician-supervised doses for a specific clinical indication.

In grey-market MT-II users, MC4R-mediated erectogenic effects are uncontrolled by dose, timing, or clinical context. Multiple case reports document priapism — erection lasting more than four hours, painful, unrelated to sexual stimulation — requiring emergency urological intervention. Prolonged priapism causes ischemic damage to penile tissue if not treated promptly (aspiration and/or intracavernosal injection by a urologist). These are documented adverse events in the published medical literature, not theoretical risks.

The only approved compound in this class

Afamelanotide (Scenesse, CLINUVEL Pharmaceuticals) is a linear 13-amino-acid melanocortin analog. It has a relatively more selective MC1R profile compared to MT-II's pan-melanocortin agonism.

EMA approval (2014): erythropoietic protoporphyria (EPP) — a rare genetic photodermatosis caused by ferrochelatase deficiency, producing protoporphyrin IX accumulation and extreme light-induced pain. MC1R agonism increases melanin synthesis, attenuating phototoxic free-radical damage from light exposure.
FDA approval (2019): same indication — EPP.
Delivery: 16 mg subcutaneous implant, physician-administered, every 60 days.
Not approved for tanning or cosmetic darkening. The EPP approval is narrow and specific to a rare, painful medical condition.

The existence of an approved drug in the melanocortin class does not validate MT-II. Different compound, different selectivity, different safety dataset, different regulatory review, different indication. Our afamelanotide spoke (5.8) covers the approved drug's clinical evidence and EPP indication in full.

Regulatory summary

Agency	Country/Region	Status
FDA	United States	Not approved for any indication; sold as research chemical (unapproved status)
EMA	European Union	Not approved; EMA safety communications issued
MHRA	United Kingdom	Safety advisory 2009; effectively prohibited for human use
TGA	Australia	Multiple safety warnings; illegal for human use without TGA registration
Swissmedic	Switzerland	Not authorised
Health Canada	Canada	Not approved; sold as research chemical only

Context: why MT-II persists in the research-chemical market

Despite the adverse event literature and regulatory warnings, MT-II continues to be sold as a research chemical. Understanding why does not mean accepting that use is safe:

The tanning effect is real and rapid. MC1R agonism produces measurable skin darkening within 1–2 weeks of use in most individuals. A cosmetic effect this visible creates persistent consumer demand regardless of risk profile.

Most users do not develop melanoma. Melanoma development is probabilistic — not every MC1R stimulation event causes cancer. Many MT-II users do not experience serious adverse events. This creates survivorship-bias reasoning that obscures the risk for those who do experience adverse events, including those who may never connect a melanoma diagnosis to prior MT-II use.

RUO framing creates a legal pathway. Research-chemical vendors sell MT-II under "research use only" framing. Whether personal tanning use constitutes legitimate research use is not settled law in most jurisdictions.

None of these factors make MT-II safe or approved. They explain market persistence without validating risk acceptability.

Frequently asked

Is Melanotan 2 the same as afamelanotide?

No. They are different compounds with different amino acid sequences, different receptor selectivity profiles (MT-II is pan-melanocortin; afamelanotide is more MC1R-selective), different safety datasets, different regulatory histories, and different indications. Afamelanotide is FDA- and EMA-approved for erythropoietic protoporphyria. MT-II is not approved for any indication by any regulatory agency. The shared class (both are melanocortin receptor agonists) does not make them equivalent or interchangeable.

Can using MT-II cause melanoma?

Published case reports — including Langan et al. 2009 (BMJ) and additional case series — document new melanomas and accelerated progression of dysplastic nevi in MT-II users. Case reports do not establish causation, but they represent a serious pharmacovigilance signal that regulators in the UK, Australia, and EU took seriously enough to issue warnings. The mechanism is biologically plausible: MC1R agonism drives melanocyte proliferation, which could accelerate dysplastic-to-malignant transition. Anyone with a personal or family history of melanoma or multiple dysplastic nevi should treat MC1R agonists — including MT-II — as a significant risk.

What is priapism, and how is it linked to MT-II?

Priapism is a prolonged erection unrelated to sexual stimulation, lasting more than four hours, painful, potentially damaging to penile tissue if untreated. MT-II stimulates MC4R in hypothalamic circuits mediating penile erection. Multiple case reports in the medical literature describe priapism in MT-II users requiring emergency urological intervention (aspiration and intracavernosal injection). The frequency is not established from controlled incidence data — it is a case-report-documented adverse event — but it is a genuine documented risk, not a theoretical concern.

Is it legal to buy Melanotan 2?

In the US, MT-II is sold as a research chemical under RUO framing. Its legal status for personal use is not clearly settled and is subject to FDA enforcement discretion regarding unapproved drugs. In Australia, it is effectively prohibited for human use and TGA has seized products. In the UK, following MHRA warnings, it is effectively prohibited. Legal availability and legal use for human purposes are different questions in every jurisdiction. "Available to purchase" does not mean "legal for human use."

How does MT-II compare to self-tanning products?

Topical self-tanners (DHA-based) produce cosmetic skin darkening through a chemical reaction with dead stratum corneum cells. They have no melanocyte activity, no receptor pharmacology, and no associated adverse event literature beyond occasional irritation. MT-II produces biological melanin synthesis through MC1R agonism — a pharmacological mechanism with documented adverse events including melanoma case reports. The visual cosmetic result may appear similar; the biology and risk profile are entirely different.

Reviewer sign-off Reviewed 2026-04-18 by the PeptideRadar Research Desk. This is the most safety-critical page in the Skin & Dermatological pillar. Primary adverse event citations: Langan EA et al. 2009 (BMJ, 338:b277); UK MHRA Safety Advisory on Melanotan products (2009); Australian TGA Safety Alerts on tanning injections. Pharmacology citations: Dorr RT et al. (University of Arizona, original MT-II characterisation publications); Hadley ME & Hruby VJ (melanocortin peptide pharmacology). Afamelanotide approval data: CLINUVEL Pharmaceuticals Phase III EPP trial data; FDA NDA approval 2019. This page does not contain a use protocol. Our spoke 5.19 addresses published pharmacological dosing data as research reference only. Corrections: corrections@peptideradar.net.